Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. MYND Lifesciencs Inc.
  6. News
  7. Summary
    MYND   CA62857B1094

MYND LIFESCIENCS INC.

(MYND)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics

06/17/2021 | 07:00am EDT

MYND Life Sciences Inc. announced a Letter of Intent ("LOI") with Eyam Vaccines and Immunotherapeutics ("Eyam"). The LOI outlines an Exclusive Licensing Agreement with respect to Eyam's proprietary technologies for applications to Central Nervous System Vaccines ("CNSV"). The terms of the LOI state Eyam will grant MYND an exclusive license to manufacture and distribute its CNSV globally for 20 years with a mutual option to extend upon the expiration of the agreement, in exchange for mutually agreed upon royalty payments and research and development commitments to be determined as part of the Definitive Agreement.


ę S&P Capital IQ 2021
All news about MYND LIFESCIENCS INC.
10/18KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Vie..
AQ
10/11KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
AQ
10/07MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidi..
CI
09/29MYND LIFE SCIENCES INC : . Announces RSU Grant
AQ
09/09MYND Lifesciencs Inc. announced that it has received CAD 2.7 million in funding
CI
08/26MYND LIFESCIENCS : Life Sciences Announces $3 Million Convertible Debenture Unit Offering
AQ
08/26MYND Lifesciencs Inc. announced that it expects to receive CAD 3 million in funding
CI
08/11MYND LIFESCIENCS : Life Sciences Announces DTC Eligibility
AQ
06/23MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer's disease
CI
06/17MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics
CI
More news
Financials
Sales 2020 - - -
Net income 2020 0,00 M 0,00 M 0,00 M
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 39,0 M 31,6 M 31,6 M
Capi. / Sales 2019 -
Capi. / Sales 2020 -
Nbr of Employees 10
Free-Float -
Chart MYND LIFESCIENCS INC.
Duration : Period :
MYND Lifesciencs Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Lyle Oberg Chief Executive Officer & Director
Paul Ciullo Chief Financial Officer & Secretary
Wilfred A. Jefferies Chairman & Chief Science Officer
Jordan Cleland Chief Operating Officer
Aaron Bowden Independent Director